News

Ravina Kullar, PharmD, MPH, reflects on rapid advances in COVID-19 treatment understanding during IDWeek 2020.

New data suggest collaboration between hospital prescribers and stewardship teams is still not perfected.

New data show the pandemic, and a lack of efficacious therapies, did harm to 4 years' worth of stewardship.

Investigators wanted to examine spontaneously reported adverse events and whether they were cause for concern.

The conclusion to the independent safety review punctuates a 50-day period of scrutiny and discussion around 2 non-fatal adverse events reported in patients.

Here is a look at the patterns within the variety of symptoms and presentations during physician exams.

A presenting author offers greater study insights into this novel therapy for the treatment of serious infections.

The study population comprised 224 patients admitted to the ICU with influenza, and the overall rate of IPA was 3.1% (7/224).

Its phase 3 COVE trial enrollment is complete and the company is working towards its goal of FDA approval.

“The compound appears to be safe and well-tolerated, [and we observed] excellent efficacy based on a very small sample size,” Peter G. Pappas, MD, said.

The urgent care setting is a prime target for antimicrobial stewardship efforts as it becomes an increasingly prevalent form of healthcare delivery.

A firsthand look into a Kentucky program that's initiated opioid use disorder care in recurring HIV, hepatitis C patients.

The full approval is based on 3 randomized controlled trials showing benefit of remdesivir compared with placebo across multiple outcome assessments.

New data highlight the need for more antimicrobial stewardship adoption in emergency care settings.

Results from the Pivotal ADAPT-PO study were reported.

Results show medication provides therapeutic response for Candida.

In an effort to expand serotype coverage beyond 13, a 20-valent pneumococcal conjugate vaccine, PCV20, is currently in development.

Overall, 88% of participants who received long-acting therapy preferred CAB LA+RPV LA compared with oral treatment.

The results support B/F/TAF as a switch option for Black Americans who are virologically suppressed, including individuals with a history of treatment failure or pre-existing resistance.

How has the COVID-19 pandemic affected clinical trial site restrictions, drug delivery, dosing, patient monitoring, and follow-up?

New data presented at IDWeek showed more than half observed households with a COVID-19 case reported a secondary infection, oftentimes within 3 days.

Phase 1 data and a history of benefit for worsening respiratory infections show promise for the therapy.

New head-to-head phase 3 data show a promising potential new HBV vaccine may join the market in the near future.

In a large nursing home study, asymptomatic and symptomatic residents were found to carry similar viral loads.

New data show ADA-recommended oral care for inpatients is associated with an 85% reduction in NVHAP infections at an 800-bed medical center over a year.

A study looked at weight gain when changing therapy regimens.

The participant was taking a placebo and the trial will continue according to initial reports.